Haneen A. Al-Mazroua

发表

Mitogen-activated protein kinase inhibitor PD98059 improves neuroimmune dysfunction in experimental autoimmune encephalomyelitis in SJL/J mice through the inhibition of nuclear factor-kappa B signaling in B cells

A. Nadeem, S. Attia, Khalid Alhazzani, 2023, Brain Research Bulletin.

CCR1 antagonist ameliorates experimental autoimmune encephalomyelitis by inhibition of Th9/Th22-related markers in the brain and periphery.

A. Nadeem, N. Ali, S. Attia, 2022, Molecular immunology.

5-Aminoisoquinolinone, a PARP-1 Inhibitor, Ameliorates Immune Abnormalities through Upregulation of Anti-Inflammatory and Downregulation of Inflammatory Parameters in T Cells of BTBR Mouse Model of Autism

A. Nadeem, S. Attia, Khalid Alhazzani, 2021, Brain sciences.

Involvement of CD45 cells in the development of autism spectrum disorder through dysregulation of granulocyte-macrophage colony-stimulating factor, key inflammatory cytokines, and transcription factors.

A. Nadeem, L. Al-Ayadhi, S. Attia, 2020, International immunopharmacology.

Cadmium Exposure Is Associated with Behavioral Deficits and Neuroimmune Dysfunction in BTBR T+ Itpr3tf/J Mice

A. Nadeem, S. Attia, M. Alanazi, 2023, International journal of molecular sciences.

A potent and selective CXCR2 antagonist improves neuroimmune dysregulation through the inhibition of NF-κB and notch inflammatory signaling in the BTBR mouse model of autism

A. Nadeem, S. Attia, S. Bakheet, 2023, Journal of Neuroimmunology.

CXCR2 antagonist SB332235 mitigates deficits in social behavior and dysregulation of Th1/Th22 and T regulatory cell-related transcription factor signaling in male BTBR T+ Itpr3tf/J mouse model of autism

A. Nadeem, Sheikh F Ahmad, K. E. Ibrahim, 2022, Pharmacology Biochemistry and Behavior.

Methylmercury chloride exposure exacerbates existing neurobehavioral and immune dysfunctions in the BTBR T+ Itpr3tf/J mouse model of autism.

A. Nadeem, K. E. Ibrahim, S. Attia, 2022, Immunology letters.

Upregulation of interleukin (IL)-31, a cytokine producing CXCR1 peripheral immune cells, contributes to the immune abnormalities of autism spectrum disorder

A. Nadeem, L. Al-Ayadhi, S. Attia, 2020, Journal of Neuroimmunology.

DAPTA, a C‐C chemokine receptor 5 (CCR5) antagonist attenuates immune aberrations by downregulating Th9/Th17 immune responses in BTBR T+ Itpr3tf/J mice

A. Nadeem, M. Alshammari, S. Attia, 2019, European journal of pharmacology.

The histamine-4 receptor antagonist JNJ7777120 prevents immune abnormalities by inhibiting RORγt/T-bet transcription factor signaling pathways in BTBR T+ Itpr3tf/J mice exposed to gamma rays.

A. Nadeem, Wael A Alanazi, S. Attia, 2019, Molecular immunology.

Lead (Pb) exposure exacerbates behavioral and immune abnormalities by upregulating Th17 and NF-κB-related signaling in BTBR T+ Itpr3tf/J autistic mouse model.

A. Nadeem, S. Attia, M. Algahtani, 2022, Neurotoxicology.

CXCR3 antagonist NBI-74330 mitigates joint inflammation in Collagen-Induced arthritis model in DBA/1J mice.

A. Nadeem, K. E. Ibrahim, S. Attia, 2023, International immunopharmacology.

CXC chemokine receptor 3 antagonist AMG487 shows potent anti-arthritic effects on collagen-induced arthritis by modifying B cell inflammatory profile.

A. Nadeem, H. M. Mahmood, S. Attia, 2020, Immunology letters.

CC chemokine receptor 5 antagonist alleviates inflammation by regulating IFN-γ/IL-10 and STAT4/Smad3 signaling in a mouse model of autoimmune encephalomyelitis.

A. Nadeem, S. Attia, M. Alanazi, 2022, Cellular immunology.

S3I-201, a selective stat3 inhibitor, ameliorates clinical symptoms in a mouse model of experimental autoimmune encephalomyelitis through the regulation of multiple intracellular signalling in Th1, Th17, and treg cells.

A. Nadeem, S. Attia, S. Bakheet, 2023, Multiple sclerosis and related disorders.

Downregulation of the Cardiotrophin-1 Gene Expression by Valsartan and Spironolactone in Hypertrophied Heart Rats In Vivo and Rat Cardiomyocyte H9c2 Cell Line In Vitro: A Novel Mechanism of Cardioprotection

H. Korashy, N. Al-Rasheed, H. A. Al-Mazroua, 2013, Journal of cardiovascular pharmacology.